XVIVO Perfusion (XVIVO) Q2 2026 earnings summary

Executive summary

• Q2 net sales reached SEK 239 million, up 34% year-over-year, with 36% organic growth in local currencies; thoracic and abdominal segments led growth, while services declined.

• EBITDA margin improved to 19% in Q2, with strong operating cash flow and profitability supporting ongoing investments in commercial expansion and manufacturing scale-up.

• Both thoracic and abdominal segments showed rapid growth in North America and Europe, with notable momentum in lung, heart, and kidney sales.

• Investments focused on expanding sales force, scalable production, and regulatory approvals, particularly for heart and liver products.

• Over 600 heart transplants performed globally using company technology, with strong clinical outcomes and increased adoption under derogation and compassionate use.

Financial highlights

• Q2 net sales were SEK 239 million, representing 36% organic growth; gross margin was 71%.

• EBITDA was SEK 45 million (19% margin), with EBIT at SEK 25 million and net profit at SEK 16.3 million.

• H1 2026 net sales totaled SEK 480 million, up 21% year-over-year, with EBITDA at SEK 96 million and net profit at SEK 52.6 million.

• Operating cash flow was SEK 63 million in Q2 and SEK 129 million year-to-date, with cash and cash equivalents at SEK 305 million at period end.

• Earnings per share for Q2 was SEK 0.52, and for H1 was SEK 1.67.

Outlook and guidance

• Focus remains on expanding U.S. sales force, partnerships, and adoption of EVLP and service models, with regulatory submissions for heart (FDA) and liver (U.S.) targeted for this quarter.

• Long-term demand for transplant solutions expected to remain high, with machine perfusion and service models driving future growth.

• Continued investments planned in commercial capabilities, digital offerings, and organ recovery services to support long-term growth.